Under the terms of the agreement, Innovent secures upfront payments and future milestone rewards, alongside tiered royalties on net sales. Spero gains exclusive global access to IBI355, a monoclonal antibody targeting autoimmune conditions, while Innovent maintains rights within Greater China. Spero expects to launch a Phase 2 trial for IgG4-related disease by the second quarter of 2027, complementing Innovent’s own planned trial for Sjögren’s disease in China earlier that year.

This transaction reflects a broader industry pattern where global pharmaceutical majors increasingly tap into Chinese innovation. Recent multi-billion dollar deals involving Dizal and Sino Biopharmaceutical with AstraZeneca underscore this trend. Citi analysts noted the deal validates Innovent’s autoimmune franchise, suggesting that such cross-border collaborations remain resilient despite geopolitical friction. Innovent’s stock settled 7.2% higher following the announcement, extending its year-to-date gains to approximately 26%.